Globe Life director cashes in near 52-week high, shares backed by fresh analyst targets

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-27, 09:05.

Globe Life (US37959E1029) draws attention after director Cheryl Alston disclosed sizeable insider transactions in a recent SEC filing. The stock trades on the NYSE under the ticker GL, with shares hovering near their 52-week high around 181 dollars, according to recent market data.

What the SEC filing shows

According to a report summarizing the latest Form 4 filing, Cheryl Alston, a director at Globe Life, exercised director stock options and immediately sold part of the acquired shares on June 25, 2026. Alston acquired 14,017 Globe Life shares at an exercise price of 105.56 dollars per share, representing an outlay of about 1.48 million dollars.

Following the option exercise, Alston disposed of 8,258 shares in multiple transactions at prices between 177.5608 and 180.57 dollars per share, generating total proceeds of roughly 1,480,134 dollars. The sale prices came close to Globe Life’s reported 52-week high of 181.15 dollars, a level reached after the stock delivered approximately 44.6 percent return over the past twelve months.

Analysts lift targets after Q1

In parallel with the insider activity, several research houses have updated their view on Globe Life following the insurer’s first-quarter 2026 earnings release. Globe Life reported Q1 2026 earnings per share of 3.43 dollars, missing the consensus forecast of 3.48 dollars by about 1.44 percent, while revenue of 1.56 billion dollars was broadly in line with expectations.

TD Cowen raised its price target for Globe Life shares to 215 dollars from 199 dollars and reiterated a Buy rating, citing the attractiveness of the company’s U.S. life insurance business model. BMO Capital increased its target to 150 dollars, highlighting that management lifted the midpoint of excess cash flow guidance by 4 percent to 675 million dollars, a metric closely watched by dividend and buyback-focused investors.

Truist Securities also adjusted its price target, lifting it to 185 dollars on the back of a higher EPS outlook for 2026. These moves add to a constructive analyst backdrop for Globe Life, even after the modest earnings miss, and provide an international anchor for investors monitoring U.S. life insurers alongside peers such as MetLife and Prudential Financial.

The business behind the stock

Globe Life generates most of its revenue by selling individual life insurance and supplemental health insurance products to middle-income households in the United States. The company operates through brands such as Globe Life, American Income Life, Liberty National Life and United American, distributing policies via captive agents, independent agents and direct-to-consumer channels.

Where the stock trades today

Globe Life shares (US37959E1029) trade on the NYSE at about 179.28 dollars as of the close on 2026-06-26, with after-hours indications near 178.90 dollars, based on recent quotes. That compares with a 52-week range between roughly 118 dollars and 181.15 dollars, placing the latest price close to the upper end of the band.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to engage in any securities transaction. All data are based on sources cited in the text and may change without notice.